Workload balancing: staffing ratio analysis for primary care redesign

2016 ◽  
Vol 30 (1-2) ◽  
pp. 6-29 ◽  
Author(s):  
Xiang Zhong ◽  
Hyo Kyung Lee ◽  
Molly Williams ◽  
Sally Kraft ◽  
Jeffery Sleeth ◽  
...  
2020 ◽  
pp. 2002795
Author(s):  
Fergus Hamilton ◽  
David Arnold ◽  
William Henley ◽  
Rupert A. Payne

BackgroundIschaemic stroke and myocardial infarction (MI) are common after pneumonia and are associated with long-term mortality. Aspirin may attenuate this risk and should be explored as a therapeutic option.MethodsWe extracted all patients with pneumonia, aged over 50, from the Clinical Practice Research Datalink (CPRD), a large UK primary care database, from inception until January 2019. We then performed a prior event rate ratio analysis (PERR) with propensity score matching, an approach that allows for control of measured and unmeasured confounding, with aspirin usage as the exposure, and ischaemic events as the outcome. The primary outcome was the combined outcome of ischaemic stroke and myocardial infarction. Secondary outcomes were ischaemic stroke and myocardial infarction individually. Relevant confounders were included in the analysis (smoking, comorbidities, age, gender).Findings48 743 patients were eligible for matching. 8099 of these were aspirin users who were matched to 8099 non-users. Aspirin users had a reduced risk of the primary outcome (adjusted hazard ratio, HR 0.64; 95% confidence interval 0.52–0.79) in the PERR analysis. For both secondary outcomes, aspirin use was also associated with a reduced risk HR 0.46 (0.30–0.72) and HR 0.70 (0.55–0.91) for myocardial infarction and stroke respectively).InterpretationThis study provides supporting evidence that aspirin use is associated with reduced ischaemic events after pneumonia in a primary care setting. This drug may have a future clinical role in preventing this important complication.


2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Leah Palapar ◽  
Laura Wilkinson-Meyers ◽  
Thomas Lumley ◽  
Ngaire Kerse

Abstract Background Reducing ambulatory sensitive hospitalisations (ASHs) is a strategy to control spending on hospital care and to improve quality of primary health care. This research investigated whether ASH rates in older people varied by GP and practice characteristics. Methods We identified ASHs from the national dataset of hospital events for 3755 community-dwelling participants aged 75+ enrolled in a cluster randomised controlled trial involving 60 randomly selected general practices in three regions in New Zealand. Poisson mixed models of 36-month ASH rates were fitted for the entire sample, for complex participants, and non-complex participants. We examined variation in ASH rates according to GP- and practice-level characteristics after adjusting for patient-level predictors of ASH. Results Lower rates of ASHs were observed in female GPs (IRR 0.83, CI 0.71 to 0.98). In non-complex participants, but not complex participants, practices in more deprived areas had lower ASH rates (4% lower per deprivation decile higher, IRR 0.96, CI 0.92 to 1.00), whereas main urban centre practices had higher rates (IRR 1.84, CI 1.15 to 2.96). Variance explained by these significant factors was small (0.4% of total variance for GP sex, 0.2% for deprivation, and 0.5% for area type). None of the modifiable practice-level characteristics such as home visiting and systematically contacting patients were significantly associated with ASH rates. Conclusions Only a few GP and non-modifiable practice characteristics were associated with variation in ASH rates in 60 New Zealand practices interested in a trial about care of older people. Where there were significant associations, the contribution to overall variance was minimal. It also remains unclear whether lower ASH rates in older people represents underservicing or less overuse of hospital services, particularly for the relatively well patient attending practices in less central, more disadvantaged communities. Thus, reducing ASHs through primary care redesign for older people should be approached carefully. Trial registration Australian and New Zealand Clinical Trials Register ACTRN12609000648224.


2020 ◽  
Vol 55 (S3) ◽  
pp. 1144-1154
Author(s):  
Jillian B. Harvey ◽  
Jocelyn Vanderbrink ◽  
Yasmin Mahmud ◽  
Erin Kitt‐Lewis ◽  
Laura Wolf ◽  
...  

2016 ◽  
Vol 16 (7) ◽  
pp. 616-620 ◽  
Author(s):  
Benjamin N. Fogel ◽  
Stephen Warrick ◽  
Jonathan A. Finkelstein ◽  
Melissa Klein

2019 ◽  
Vol 6 (1) ◽  
pp. 55-66
Author(s):  
James Normington ◽  
Eric Lock ◽  
Caroline Carlin ◽  
Kevin Peterson ◽  
Bradley Carlin

2014 ◽  
Vol 40 (12) ◽  
pp. 533-540 ◽  
Author(s):  
William Caplan ◽  
Sarah Davis ◽  
Sally Kraft ◽  
Stephanie Berkson ◽  
Martha Gaines ◽  
...  

2019 ◽  
Vol 15 ◽  
pp. 43-47
Author(s):  
Lisa Burkhart ◽  
Trisha Leann Horsley ◽  
Jorgia Connor ◽  
Joanne Kouba ◽  
Aaron Michelfelder ◽  
...  

2019 ◽  
Vol 17 (Suppl 1) ◽  
pp. S24-S32 ◽  
Author(s):  
Peter Chabot Smith ◽  
Corey Lyon ◽  
Aimee F. English ◽  
Colleen Conry

Sign in / Sign up

Export Citation Format

Share Document